Supportive Therapies in Multiple Myeloma

Authors: Charise Gleason NP 1 , Ajay Nooka MD, MPH 1 and Sagar Lonial MD 1
View More View Less
  • 1 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

The outlook for patients with myeloma has improved dramatically over the past few years largely because of improvements in supportive care, the use of high-dose therapy, and the introduction of the novel agents thalidomide, bortezomib, and lenalidomide. These new treatment options have changed the natural history for patients with myeloma, but clinicians must consider treatment-related toxicities. Some of the most common short- and long-term toxicities include the development of peripheral neuropathy, hematologic complications, thrombosis, and bone-related complications, such as fracture and osteonecrosis of the jaw. Careful consideration of patient-reported symptoms and appropriate dose modification or prophylaxis to prevent the development of toxicity are critical, and will result in improved quality of life and better tolerance of delivered therapy.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Sagar Lonial, MD, Emory Clinic, 1365 Clifton Road, Building C, Room 4004, Atlanta, GA 30322. E-mail: sloni01@emory.edu
  • 1

    Kumar SK, Rajkumar SV, Dispenzieri A. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:25162520.

  • 2

    Silberman J, Lonial S. Review of peripheral neuropathy in plasma cell disorders. Hematol Oncol 2008;26:5565.

  • 3

    Ricardson PG, Xie W, Mitsiades C. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:35183525.

    • Search Google Scholar
    • Export Citation
  • 4

    Richardson PG, Briemberg H, Jagannath S. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:31133120.

    • Search Google Scholar
    • Export Citation
  • 5

    Richardson PG, Sonneveld P, Schuster MW. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:24872498.

    • Search Google Scholar
    • Export Citation
  • 6

    Richardson PG, Sonneveld P, Schuster MW. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009;144:895903.

    • Search Google Scholar
    • Export Citation
  • 7

    Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112:15931599.

    • Search Google Scholar
    • Export Citation
  • 8

    Palumbo A, Bringhen S, Rossi D. A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients [abstract]. Blood 2008;112:Abstract 652.

    • Search Google Scholar
    • Export Citation
  • 9

    Mateos MV, Oriol A, Martinez J. Bortezomib (Velcade)-melphalan-prednisone (VMP) versus velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for velcade: an alkylating or an immunomodulator agent? [abstract]. Blood 2008;112:Abstract 651.

    • Search Google Scholar
    • Export Citation
  • 10

    Pineda-Roman M, Zangari M, van Rhee F. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008;22:14191427.

    • Search Google Scholar
    • Export Citation
  • 11

    Palumbo A, Facon T, Sonneveld P. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008;111:39683977.

  • 12

    Mileshkin L, Stark R, Day B. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:45074514.

    • Search Google Scholar
    • Export Citation
  • 13

    Tariman JD, Love G, McCullagh E, Sandifer S. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 2008;12:2936.

    • Search Google Scholar
    • Export Citation
  • 14

    Zou W, Yue P, Lin N. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 2006;12:273280.

  • 15

    Levine S, Saltzman A. Pyridoxine (vitamin B6) neurotoxicity: enhancement by protein-deficient diet. J Appl Toxicol 2004;24:497500.

  • 16

    Lonial S, Waller EK, Richardson PG. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106:37773784.

    • Search Google Scholar
    • Export Citation
  • 17

    Lonial S, Richardson PG, San Miguel J. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 2008;143:222229.

    • Search Google Scholar
    • Export Citation
  • 18

    Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther 2006;6:11651173.

  • 19

    Richardson PG, Schlossman RL, Weller E. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:30633067.

    • Search Google Scholar
    • Export Citation
  • 20

    Richardson PG, Blood E, Mitsiades CS. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:34583464.

    • Search Google Scholar
    • Export Citation
  • 21

    Dimopoulos M, Spencer A, Attal M. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:21232132.

    • Search Google Scholar
    • Export Citation
  • 22

    Weber DM, Chen C, Niesvizky R. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:21332142.

    • Search Google Scholar
    • Export Citation
  • 23

    Mateos M, García-Sanz R, Colado E. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Br J Haematol 2008;140:324326.

    • Search Google Scholar
    • Export Citation
  • 24

    Katodritou E, Verrou E, Hadjiaggelidou C. Erythopoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 2008;87:961973.

    • Search Google Scholar
    • Export Citation
  • 25

    Shehata N, Walker I, Meyer R. The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review. Ann Hematol 2008;87:961973.

    • Search Google Scholar
    • Export Citation
  • 26

    Kumar S, Giralt S, Stadtmauer EA. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009;114:17291735.

    • Search Google Scholar
    • Export Citation
  • 27

    Mazumder A, Kaufman J, Niesvizky R. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2007;22:12801281.

    • Search Google Scholar
    • Export Citation
  • 28

    Rajkumar SV, Jacobus S, Callander N. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome wi [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 8504.

    • Search Google Scholar
    • Export Citation
  • 29

    Orciuolo E, Galimberti S, Petrini M. Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro. Leuk Res 2007;31:10261027.

    • Search Google Scholar
    • Export Citation
  • 30

    Straube C, Wehner R, Wendisch M. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia 2007;21:14641471.

    • Search Google Scholar
    • Export Citation
  • 31

    Oakervee HE, Popat R, Curry N. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755762.

    • Search Google Scholar
    • Export Citation
  • 32

    Popat R, Oakervee HE, Hallam S. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008;141:512516.

    • Search Google Scholar
    • Export Citation
  • 33

    Chanan-Khan A, Sonneveld P, Schuster MW. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:47844790.

    • Search Google Scholar
    • Export Citation
  • 34

    San Miguel JF, Schlag R, Khuageva NK. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906917.

    • Search Google Scholar
    • Export Citation
  • 35

    Zonder JA. Thrombotic complications of myeloma therapy. Hematology Am Soc Hematol Educ Program 2006:348355.

  • 36

    Singhal S, Mehta J, Desikan R. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:15651571.

  • 37

    Rajkumar SV, Blood E, Vesole D. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431436.

    • Search Google Scholar
    • Export Citation
  • 38

    Zangari M, Siegel E, Barlogie B. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:11681171.

    • Search Google Scholar
    • Export Citation
  • 39

    Zonder JA, Crowley J, Hussein MA. Superiority of lenalidomide (len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 [abstract]. Blood 2007;110:Abstract 77.

    • Search Google Scholar
    • Export Citation
  • 40

    Rajkumar SV, Jacobus S, Callander N. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood 2007;110:Abstract 74.

    • Search Google Scholar
    • Export Citation
  • 41

    Palumbo A, Rajkumar SV, Dimopoulos MA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414423.

    • Search Google Scholar
    • Export Citation
  • 42

    Sezer O. Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist 2009;14:276283.

  • 43

    Roodman GD. Novel targets for myeloma bone disease. Expert Opin Ther Targets 2008;12:13771387.

  • 44

    Jantunen E, Lahtinen R, Laakso M. Use of clodronate in multiple myeloma. Leuk Lymphoma 1995;19:207211.

  • 45

    Plosker GL, Goa KL. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994;47:945982.

    • Search Google Scholar
    • Export Citation
  • 46

    Berenson JR, Lichtenstein A, Porter L. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488493.

    • Search Google Scholar
    • Export Citation
  • 47

    Berenson JR, Rosen LS, Howell A. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:11911200.

    • Search Google Scholar
    • Export Citation
  • 48

    Mehrotra B, Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program 2006:356360.

    • Search Google Scholar
    • Export Citation
  • 49

    Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:186193.

    • Search Google Scholar
    • Export Citation
  • 50

    Hoff AO, Toth BB, Altundag K. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826836.

    • Search Google Scholar
    • Export Citation
  • 51

    Dimopoulos MA, Kastritis E, Bamia C. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117120.

    • Search Google Scholar
    • Export Citation
  • 52

    Kyle RA, Yee GC, Somerfield MR. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:24642472.

    • Search Google Scholar
    • Export Citation
  • 53

    Harousseau JL, Attal M, Leleu X. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:14981505.

    • Search Google Scholar
    • Export Citation
  • 54

    Rosinol L, Oriol A, Mateos MV. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007;25:44524458.

    • Search Google Scholar
    • Export Citation
  • 55

    Mikhael JR, Belch AR, Prince HM. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009;144:169175.

    • Search Google Scholar
    • Export Citation
  • 56

    Orlowski RZ, Nagler A, Sonneveld P. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:38923901.

    • Search Google Scholar
    • Export Citation
  • 57

    Offidani M, Corvatta L, Marconi M. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 2004;72:403409.

    • Search Google Scholar
    • Export Citation
  • 58

    Tosi P, Zamagni E, Cellini C. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005;74:212216.

    • Search Google Scholar
    • Export Citation
  • 59

    Richardson P, Schlossman R, Jagannath S. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004;79:875882.

    • Search Google Scholar
    • Export Citation
  • 60

    Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99102; discussion 199–102.

  • 61

    Bamias A, Kastritis E, Bamia C. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:85808587.

    • Search Google Scholar
    • Export Citation
  • 62

    Badros A, Weikel D, Salama A. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945952.

    • Search Google Scholar
    • Export Citation
  • 63

    Dimopoulos MA, Kastritis E, Anagnostopoulos A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968971.

    • Search Google Scholar
    • Export Citation
  • 64

    Zervas K, Verrou E, Teleioudis Z. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620623.

    • Search Google Scholar
    • Export Citation
  • 65

    Tosi P, Zamagni E, Cangini D. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 2006;108:39513952.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 507 429 44
PDF Downloads 200 170 9
EPUB Downloads 0 0 0